CRISPR genome-wide screening identifies dependence on the proteasome subunit PSMC6 for bortezomib sensitivity in multiple myeloma

Chang Xin Shi, K. Martin Kortüm, Yuan Xiao Zhu, Laura A. Bruins, Patrick Jedlowski, Patrick G. Votruba, Moulun Luo, Robert A. Stewart, Jonathan Ahmann, Esteban D Braggio, Alexander Keith Stewart

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Bortezomib is highly effective in the treatment of multiple myeloma; however, emergent drug resistance is common. Consequently, we employed CRISPR targeting 19,052 human genes to identify unbiased targets that contribute to bortezomib resistance. Specifically, we engineered an RPMI8226 multiple myeloma cell line to express Cas9 infected by lentiviral vector CRISPR library and cultured derived cells in doses of bortezomib lethal to parental cells. Sequencing was performed on surviving cells to identify inactivated genes responsible for drug resistance. From two independent whole-genome screens, we selected 31 candidate genes and constructed a second CRISPR sgRNA library, specifically targeting each of these 31 genes with four sgRNAs. After secondary screening for bortezomib resistance, the top 20 "resistance" genes were selected for individual validation. Of these 20 targets, the proteasome regulatory subunit PSMC6 was the only gene validated to reproducibly confer bortezomib resistance. We confirmed that inhibition of chymotrypsin-like proteasome activity by bortezomib was significantly reduced in cells lacking PSMC6. We individually investigated other members of the PSMC group (PSMC1 to 5) and found that deficiency in each of those subunits also imparts bortezomib resistance. We found 36 mutations in 19S proteasome subunits out of 895 patients in the IA10 release of the CoMMpass study (https://themmrf.org). Our findings demonstrate that the PSMC6 subunit is the most prominent target required for bortezomib sensitivity in multiple myeloma cells and should be examined in drug-refractory populations.

Original languageEnglish (US)
Pages (from-to)2862-2870
Number of pages9
JournalMolecular Cancer Therapeutics
Volume16
Issue number12
DOIs
StatePublished - Dec 1 2017

Fingerprint

Clustered Regularly Interspaced Short Palindromic Repeats
Proteasome Endopeptidase Complex
Multiple Myeloma
Genome
Genes
Drug Resistance
Bortezomib
Chymotrypsin
Libraries
Cultured Cells
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

CRISPR genome-wide screening identifies dependence on the proteasome subunit PSMC6 for bortezomib sensitivity in multiple myeloma. / Shi, Chang Xin; Kortüm, K. Martin; Zhu, Yuan Xiao; Bruins, Laura A.; Jedlowski, Patrick; Votruba, Patrick G.; Luo, Moulun; Stewart, Robert A.; Ahmann, Jonathan; Braggio, Esteban D; Stewart, Alexander Keith.

In: Molecular Cancer Therapeutics, Vol. 16, No. 12, 01.12.2017, p. 2862-2870.

Research output: Contribution to journalArticle

Shi, Chang Xin ; Kortüm, K. Martin ; Zhu, Yuan Xiao ; Bruins, Laura A. ; Jedlowski, Patrick ; Votruba, Patrick G. ; Luo, Moulun ; Stewart, Robert A. ; Ahmann, Jonathan ; Braggio, Esteban D ; Stewart, Alexander Keith. / CRISPR genome-wide screening identifies dependence on the proteasome subunit PSMC6 for bortezomib sensitivity in multiple myeloma. In: Molecular Cancer Therapeutics. 2017 ; Vol. 16, No. 12. pp. 2862-2870.
@article{6d20fdaaa36046bf910ece960deac9f5,
title = "CRISPR genome-wide screening identifies dependence on the proteasome subunit PSMC6 for bortezomib sensitivity in multiple myeloma",
abstract = "Bortezomib is highly effective in the treatment of multiple myeloma; however, emergent drug resistance is common. Consequently, we employed CRISPR targeting 19,052 human genes to identify unbiased targets that contribute to bortezomib resistance. Specifically, we engineered an RPMI8226 multiple myeloma cell line to express Cas9 infected by lentiviral vector CRISPR library and cultured derived cells in doses of bortezomib lethal to parental cells. Sequencing was performed on surviving cells to identify inactivated genes responsible for drug resistance. From two independent whole-genome screens, we selected 31 candidate genes and constructed a second CRISPR sgRNA library, specifically targeting each of these 31 genes with four sgRNAs. After secondary screening for bortezomib resistance, the top 20 {"}resistance{"} genes were selected for individual validation. Of these 20 targets, the proteasome regulatory subunit PSMC6 was the only gene validated to reproducibly confer bortezomib resistance. We confirmed that inhibition of chymotrypsin-like proteasome activity by bortezomib was significantly reduced in cells lacking PSMC6. We individually investigated other members of the PSMC group (PSMC1 to 5) and found that deficiency in each of those subunits also imparts bortezomib resistance. We found 36 mutations in 19S proteasome subunits out of 895 patients in the IA10 release of the CoMMpass study (https://themmrf.org). Our findings demonstrate that the PSMC6 subunit is the most prominent target required for bortezomib sensitivity in multiple myeloma cells and should be examined in drug-refractory populations.",
author = "Shi, {Chang Xin} and Kort{\"u}m, {K. Martin} and Zhu, {Yuan Xiao} and Bruins, {Laura A.} and Patrick Jedlowski and Votruba, {Patrick G.} and Moulun Luo and Stewart, {Robert A.} and Jonathan Ahmann and Braggio, {Esteban D} and Stewart, {Alexander Keith}",
year = "2017",
month = "12",
day = "1",
doi = "10.1158/1535-7163.MCT-17-0130",
language = "English (US)",
volume = "16",
pages = "2862--2870",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - CRISPR genome-wide screening identifies dependence on the proteasome subunit PSMC6 for bortezomib sensitivity in multiple myeloma

AU - Shi, Chang Xin

AU - Kortüm, K. Martin

AU - Zhu, Yuan Xiao

AU - Bruins, Laura A.

AU - Jedlowski, Patrick

AU - Votruba, Patrick G.

AU - Luo, Moulun

AU - Stewart, Robert A.

AU - Ahmann, Jonathan

AU - Braggio, Esteban D

AU - Stewart, Alexander Keith

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Bortezomib is highly effective in the treatment of multiple myeloma; however, emergent drug resistance is common. Consequently, we employed CRISPR targeting 19,052 human genes to identify unbiased targets that contribute to bortezomib resistance. Specifically, we engineered an RPMI8226 multiple myeloma cell line to express Cas9 infected by lentiviral vector CRISPR library and cultured derived cells in doses of bortezomib lethal to parental cells. Sequencing was performed on surviving cells to identify inactivated genes responsible for drug resistance. From two independent whole-genome screens, we selected 31 candidate genes and constructed a second CRISPR sgRNA library, specifically targeting each of these 31 genes with four sgRNAs. After secondary screening for bortezomib resistance, the top 20 "resistance" genes were selected for individual validation. Of these 20 targets, the proteasome regulatory subunit PSMC6 was the only gene validated to reproducibly confer bortezomib resistance. We confirmed that inhibition of chymotrypsin-like proteasome activity by bortezomib was significantly reduced in cells lacking PSMC6. We individually investigated other members of the PSMC group (PSMC1 to 5) and found that deficiency in each of those subunits also imparts bortezomib resistance. We found 36 mutations in 19S proteasome subunits out of 895 patients in the IA10 release of the CoMMpass study (https://themmrf.org). Our findings demonstrate that the PSMC6 subunit is the most prominent target required for bortezomib sensitivity in multiple myeloma cells and should be examined in drug-refractory populations.

AB - Bortezomib is highly effective in the treatment of multiple myeloma; however, emergent drug resistance is common. Consequently, we employed CRISPR targeting 19,052 human genes to identify unbiased targets that contribute to bortezomib resistance. Specifically, we engineered an RPMI8226 multiple myeloma cell line to express Cas9 infected by lentiviral vector CRISPR library and cultured derived cells in doses of bortezomib lethal to parental cells. Sequencing was performed on surviving cells to identify inactivated genes responsible for drug resistance. From two independent whole-genome screens, we selected 31 candidate genes and constructed a second CRISPR sgRNA library, specifically targeting each of these 31 genes with four sgRNAs. After secondary screening for bortezomib resistance, the top 20 "resistance" genes were selected for individual validation. Of these 20 targets, the proteasome regulatory subunit PSMC6 was the only gene validated to reproducibly confer bortezomib resistance. We confirmed that inhibition of chymotrypsin-like proteasome activity by bortezomib was significantly reduced in cells lacking PSMC6. We individually investigated other members of the PSMC group (PSMC1 to 5) and found that deficiency in each of those subunits also imparts bortezomib resistance. We found 36 mutations in 19S proteasome subunits out of 895 patients in the IA10 release of the CoMMpass study (https://themmrf.org). Our findings demonstrate that the PSMC6 subunit is the most prominent target required for bortezomib sensitivity in multiple myeloma cells and should be examined in drug-refractory populations.

UR - http://www.scopus.com/inward/record.url?scp=85037690392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037690392&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-17-0130

DO - 10.1158/1535-7163.MCT-17-0130

M3 - Article

VL - 16

SP - 2862

EP - 2870

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -